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ABSTRACT 
Purpose: Alteration of liver function during pro- 
gression of hepatocellular carcinoma (HCC) and 
cirrhosis affects the serum glycoprotein pattern. In 
this study, the changes in the N-glycome in liver tis- 
sue from patients with hepatocellular carcinoma and 
cirrhosis caused by hepatitis B virus infection were 
investigated to find out the relationship between this 
maker and liver disease. Methods: Twenty patients, 
11 with cirrhosis and 9 with hepatocellular carci-
noma, and 15 healthy donors were involved in this 
study. Liver protein N-glycans were profiled using 
the DSA-FACE technique developed in our labora-
tory. To further analyze the fucosylation status of 
these liver glycans Western lectin blots of total liver 
proteins were performed using Aspergillus oryzae 
lectin (AOL) as probe, which is a carbohydrate- 
binding protein that recognizes specifically α-1,6-fu- 
cosylated glycans. Results: The N-glycome of liver 
proteins in patients with HBV related HCC and 
cirrhosis was analyzed. Compared with healthy do-
nors, the N-glycome had significantly less (p < 0.05) 
high mannose (M8) in both groups of patients. The 
total core α-1,6-fucosy-lation in total liver glycopro-
teins was dramatically increased during the progress 
of hepatocellular carcinoma and cirrhosis compared 
to the controls. Conclusion: These results show that 
fucosylation not only increases in serum proteins but 
also in liver tissue itself of patients with HBV related 
HCC and cirrhosis. 
Keywords: N-Glycome; DSA-FACE; Fucosylation, 
HCC; Cirrhosis 
1. INTRODUCTION 
Hepatocellular carcinoma (HCC) is a primary cancer of 
the liver and is one of the leading causes of death world- 
wide [1]. HCC arises most commonly in cirrhotic livers 
following infection with hepatitis B virus (HBV) or he- 
patitis C virus (HCV) [2,3]. Like any other cancer, HCC 
develops when a mutation in the cellular machinery 
causes the cell to replicate at a higher rate and/or results 
in the cell avoiding apoptosis. In particular, chronic in- 
fections with HBV and/or HCV could evolve to malig-
nancy by repeatedly causing the immune system to at- 
tack the liver cells.  
Hepatocarcinogenesis is a complex process associated 
with accumulation of genetic and epigenetic changes that 
occur during initiation, promotion, and progression of the 
disease. Though extensive research over the past decade 
has identified a number of molecular biomarkers as well 
as cellular networks and signaling pathways affected in 
liver cancer [4], the pathophysiology of HCC is not un-
derstood clearly, but underlying liver dysfunction is a 
known predisposing condition.  
Protein N-glycosylation, the most common co-trans- 
lational modification, is the controlled enzymatic addi- 
tion of sugars to a protein. N-glycans are synthesized in 
the endoplasmic reticulum (ER) and Golgi by the se- 
quential addition of oligosaccharides, such as GlcNAc 
and fucose molecules, by the corresponding oligosac-
charyl-transferases [5,6]. The N-glycan profile in serum 
is related to the glycosylation pathway in liver cells and 
B-cells, and changes in the levels of the enzymes of this 
pathway could lead to modifications in both the core and 
outer arm structures of glycans. 
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Because the sugar chains of glycoproteins are impor- 
tant for maintaining the ordered “social behavior” of dif- 
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ferentiated cells in multicellular organisms, alterations in 
these sugar chains contribute to the molecular basis of 
abnormalities, such as invasion of tumor cells into the 
surrounding tissues and their metastasis. Alterations in 
the N-linked sugar chains are indeed found in various 
tumors [8-11]. Moreover, our and other studies recently 
showed that certain changes in the N-glycans of total 
serum glycoproteins are indicative of human HCC [7,8], 
non-alcoholic steatohepatitis (NASH) [9], liver fibrosis 
[10], and cirrhosis [11]. These observations are in line 
with the fact that a large fraction of serum proteins is 
produced by hepatocytes. 
To further explore the glycoproteome, and to clearly 
link N-glycosylation changes in serum to the liver, not 
serum proteins but liver proteins themselves are studied. 
This has been the bottleneck of many studies since liver 
tissue is far harder to collect than serum and also techni-
cally liver glycosylation is more difficult to analyze. In 
this study, the N-linked glycans in liver samples of 
HBV-infected cirrhosis and HCC patients were analyzed. 
Our results demonstrate glycosylation alterations and 
increased fucosylation in glycans of the liver in patients 
with HCC, clearly linking alterations in serum N-gly- 
come to the liver.  
2. MATERIALS AND METHODS 
2.1. Patients and Controls 
This study included 20 patients (11 with cirrhosis and 9 
with hepatocellular carcinoma caused by HBV infec- 
tion) and 15 liver donors, all of whom underwent percu- 
taneous liver biopsy at the Beijing Youan Hospital be-  
tween 2008 and 2009. The study was approved by the 
Ethics Committee of Peking University Health Science 
Centre and by the Ethics Committee of Beijing Youan 
Hospital. Informed consent was obtained from all the 
volunteers.  
2.2. Laboratory Tests  
The main clinical and biological data of the patients are 
summarized in Table 1. All patients were diagnosed as 
HBV-related cirrhosis and HBV infection was diagnosed 
by serological detection of HBsAg, anti-HBsAg (HBsAb), 
HBeAg, anti-HBeAg (HbeAb), anti-HBcAg (HBcAb) and 
HBV DNA. The extent of liver damage was assessed by 
measurement of alanine aminotransferase (ALT), aspartate 
aminotransferase (AST), total bilirubin, albumin, total se-
rum protein, and γ-glutamyltransferase (GGT). 
The diagnosis of cirrhosis was made by histological 
examination, imaging procedures, and several liver func- 
tion tests. Liver samples were evaluated independently 
by two experienced hepatopathologists who were un- 
aware of the glycomics results. Liver cirrhosis pa- tients 
(n = 10) were staged according to the Child-Pugh classi- 
fycation. Cirrhosis patients with HCC (n = 9) were diag- 
nosed by a combination of histological examination of 
biopsies, ultrasonography and/or computed tomographic 
scanning, and measurement of AFP. 
2.3. Preparation of Proteins from Liver Biopsies 
About 50 mg of liver tissue was disrupted in a mixer on 
ice in 250 µl of lysis buffer: 1% NP40, 200 mM NaCl, 
10 mM Tris-HCl pH 7.5, 5 mM EDTA, 10% glycerol, 
 
Table 1. Main clinical and biological data of the patients with HBV related cirrhosis and HCC. 
Case Group HCC Cirrhosis p Value 
Case number 9 11  
Gender (M/F) 8/1 6/5  
Age (years) 50.56 ± 6.80 48.55 ± 11.17 0.909 
HBsAg (%) 66.67 36.36  
HbsAb (%) 33.33 45.45  
HbeAg (%) 33.33 18.18  
AST (IU/L) 49.44 ± 22.71 75.55 ± 79.66 0.909 
ALT (IU/L) 47.57 ± 28.02 61.82 ± 60.13 0.970 
AST vs ALT 1.20 ± 0.46 1.24 ± 0.40 0.828 
GGT (IU/L) 102.36 ± 52.41 62.85 ± 49.40 0.200 
Albumin (g/L) 34.73 ± 4.69 32.79 ± 4.91 0.307 
HBV DNA 4.71E2± 1.75E2 1.10E5 ± 2.19E5 0.219 
Total bilirubin (µmol/L) 23.41 ± 11.49 139.19 ± 174.88 0.074 
Total serum protein (g/L) 67.19 ± 7.16 60.28 ± 10.35 0.323 
AFP (ng/ml) 2610.08 ± 6726.56 18.20 ± 43.86 0.001 
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and protease inhibitor cocktail (Complete, EDTA-free, 
Roche). Lysates were spun down for 20 min at 14,000 
rpm at 4˚C. Supernatant was collected and the concen- 
tration of the proteins measured with a BCA protein As- 
say Kit (Pierce). Samples containing 150 µg proteins 
were concentrated in a vacuum dryer to 5 µl and used in 
DSA-FACE. For sialidase digestion, 1 µl of APTS-la- 
beled sugar was used. 
2.4. Processing Liver Tissue Samples for Protein 
N-Glycome Analysis 
The N-glycans present on the proteins in 5 l of liver 
protein extract were released, labeled and analyzed by 
DSA-FACE as described previously [12,13], but with 
some minor modification. Briefly, 5 l of liver protein 
was placed in a PCR tube containing 2 l of buffer (10 
mM NH4HCO3, pH 8.3, 5% SDS) and 3 l of water. The 
tube was heated at 95˚C for 5 min and cooled for 15 min 
at 4˚C in a PCR thermocycler. Then, 3 l of peptide- 
N-glycosidase F (PNGase F) was added (2.2 U/l in 10 
mM NH4HCO3, pH 8.3, containing 3.33% NP40) (New 
England Biolabs, UK). The tubes were incubated in the 
thermocycler at 37˚C for 3 h, cooled to 4˚C, and then 100 
l of water was added. Six l of the resulting solution 
was transferred to a new PCR tube and evaporated to 
dryness at 60˚C in the thermocycler (lid open). N-gly- 
cans were derivatized by adding 1 µl of labeling solution 
(1:1 mixture of 20 mM APTS; Molecular Probes, Eugene, 
OR) in 1.2 M citric acid and 1 M NaCNBH3 in dimethyl 
sulfoxide. The tightly closed tubes were incubated at 
37˚C for 16 h. The APTS labeling reaction was stopped 
by adding 100 l of water. Then, 2 µl of APTS-labeled 
solution was transferred to a new PCR tube for digestion 
with 0.25 mU Arthrobacter ureafaciens sialidase (Roche, 
Mannheim, Germany) in 5 µl of 5 mM NH4Ac, pH 5.0. 
The tube was incubated overnight at 37˚C in the ther- 
mocycler. 40 l water was added and 10 l of labeled 
N-glycans were analyzed by DNA Sequencer Assisted- 
Fluorophore Assisted Carbohydrate Electrophoresis (DSA- 
FACE) using a capillary electrophoresis (CE)-based ABI 
3130 sequencer. Data were analyzed using the Gene-
Mapper v3.7 software (Applied Biosystems, Foster city, 
CA). The heights of the 10 peaks that were detected in 
all the samples were measured to obtain a numerical de-
scription of the profiles. 
For structural analysis of APTS-labeled serum N-gly- 
cans, appropriate amounts were digested with exoglycosi- 
dases: Streptococcus pneumonia β-1,4-galactosidase (2 
mU/digest), jack bean β-N-acetylhexosaminidase (10 mU/ 
digest), S. pneumoniae β-N-acetylhexosaminidase (10 mU/ 
digest), bovine kidney α-fucosidase (2 mU/digest) and 
almond meal α-1,3/4-fucosidase (1 μU/digest) (Prozyme, 
San Leandro, CA) and -1,2-mannosidase from Tricho- 
derma reesei (home made [14]). DSA-FACE was used to 
analyze the digestion products.  
2.5. Structure Analysis of N-Glycans Using 
Exoglycosidase Digestion 
The APTS-labeled desialylated N-glycans of 1 l ob- 
tained from the DSA-FACE procedure was digested 
overnight with various mixtures of exoglycosidases in 10 
mM NH4Ac (pH 5.0) at 37˚C. The products were sepa-
rated by electrophoresis on an ABI 3130. The exoglyco-
sidases were α-1,3/4-Fucosidase (almond meal) (Glyko, 
Novato, CA, USA), which cleaves non-reducing terminal 
α-1,3/4-linked fucose, and α-1,6-Fucosidase (bovine kid- 
ney) (Glyko, Novato, CA, USA), which cleaves non-re- 
ducing terminal α-1,6-linked fucose.  
2.6. Western Lectin Blot  
Samples of 25 µg proteins extracted from frozen liver 
tissues were separated by electrophoresis in 10% sodium 
dodecyl sulfate-polyacrylamide gel. The proteins were 
then transferred to a nitrocellulose membrane for lectin 
blot analysis. The membranes were blocked overnight at 
4˚C with 3% bovine serum albumin (BSA) in Tris-buff- 
ered saline (TBS: 140 mM NaCl, 10 mM Tris-HCl) and 
then incubated for 1 h at room temperature with 5 µg/ml 
of biotinylated Aspergillus oryzae L-fucose-specific lec- 
tin (AOL) (Funakoshi Co., Ltd., Tokyo, Japan) in TBST 
buffer (TBS containing 0.05% Tween 20). After 4 
washes of 5 min each with TBST, the membranes were 
incubated with 1/1000 diluted horseradish peroxidase- 
conjugated Streptavidin (R&D Systems, Minneapolis, 
MN, USA) for 1 h at room temperature. The membranes 
were washed 4 times again with TBST and developed 
with an ECL system (Amersham Biosciences Inc., Pis- 
cataway, NJ, USA). 
2.7. Statistical Analysis 
Statistical analyses were performed with SPSS 15.0 for 
Windows software (SPSS, Chicago, IL, USA). Results 
are presented as means ± SD. All reported p-values are 
two-tailed, using a t-test for independent samples.  
3. RESULTS 
3.1. Profiles of N-Glycans in Liver Tissue 
Mature glycoproteins in the liver are synthesized in the 
ER from a variety of oligomannose N-linked glycans 
containing 5 - 9 mannose residues (high-mannose) and 
then transported to the Golgi. Further removal of man- 
nose residues in the Golgi leads to a “core” structure 
containing three mannose and two N-acetylglucosamine 
residues (GlcNAc). Elongation of this core with a variety 
of monosaccharides leads to formation of the three major 
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classes of N-linked saccharides: high-mannose oligosac- 
charides, complex oligosaccharides (in which antennae 
are initiated with GlcNAc), and hybrid oligosaccharides 
(in which only mannose is attached to the Man-α-1,6- 
arm of the core and one or two antennae are on the Man- 
α-1,3-arm).  
To verify the structure of liver N-glycans, we com- 
pared and overlaid liver N-glycan profile to that of serum 
and RNase B. As shown in Figure 1, RNase B contains 
only five different high mannose 5, 6, 7, 8 and 9 (repre- 
sented as M5, M6, M7, M8 and M9), while serum has 
most complex oligosaccharides: biantennary N-glycans 
(NGA2F, NA2 and NA2F) and triantennary N-glycans 
(NA3 and NA3F) as our previous report [7]. We found 
 
 
Figure 1. Desialylated N-glycan profiles from liver glycopro-
teins (lower panel). N-glycan profiles from RNase B (upper 
panel) and serum (middle panel) were used as controls. RNase 
B contains varies high mannose from M5 to M9. Serum con-
tains varies complex N-glycans. High mannose presented in 
RNase B and the most abundant glycans detected in serum are 
indicated. The structures of the N-glycan peaks are shown be-
low the panels. NGA2F is an agalacto, core-α-1,6-fucosylated 
biantennary glycan; NA2 is a bigalacto, biantennary glycan; 
NA2F is a bigalacto, core-α-1,6-fucosylated biantennary; NA3 
is tri-antennary; NA3F is a branching -1,3-fucosylated tri- 
antennary. The symbols used in the structural formulas are the 
following: “black square” stands for N-acetylglucosamine 
(GlcNAc); “open circle” stands for galactose; “grey triangle” 
stands for -1,3/6-linked fucose; “grey circle” stands for mannose.  
that the pattern of the desialylated N-glycans in liver 
N-glycoproteins was different from that of the serum 
N-glycan finger print (Figure 1). There were three most 
abundant N-glycans, represented as L1, L2 and L3 (Fig-
ure 1). Overlaying with N-glycan profiles of serum and 
RNase B, L1 migrated at the same site as NA2 and L2, 
and as high as mannose 8 (M8), while L3 run as high as 
mannose 9 (M9) and NA2F. These structures were fur- 
ther studied by using exoglycosidases. If L2 and L3 are 
high mannose N-glycans (M8 and M9, respectively), 
they shall disappear and generate M5 when being digested 
by α-1,2-mannosidase. Indeed, L2 was totally disap- 
peared and shifted three residues forwards to M5, con-
firming L2 represent high mannose 8 (M8). However, L3 
was diminished partially and shifted four residues to M5 
(Figure 2). Following digestion with bovine kidney  
 
 
Figure 2. Exoglycosidase sequencing of N-glycans from liver 
glycoproteins. The upper panel shows profile from RNase B as 
high mannose reference. The 2nd panel shows desialylated N- 
glycan profile from liver. The 3rd panel shows separation of 
desialylated N-glycans digested with α-1,2-mannosidase. And 
the 4th panel shows separation of desialylated N-glycans di- 
gested with α-1,2-mannosidase and bovine kidney α-1,6-fuco- 
sidase. Peak L2 contains high mannose 8 structure (M8) as it 
shifted three mannoses forwards after α-1,2-mannosidase treat- 
ment. Peak L3 is mix of two structures: high mannose glycan 
(M9) as it shifted four mannoses forwards after α-1,2-man- 
nosidase treatment and α-1,6-fucosylated structure as it shifted 
one residue forwards to L1. The arrow lines indicate the changes 
in the glycan peaks due to glycosidase digestion.  
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α-1,6-fucosidase which can remove only one α-1,6- 
fucose from the core N-acetylglucosamine, remained part 
of L3 was then disappeared and shifted one residue for- 
ward to L1, indicating L3 contains a mixture of M9 and 
core-fucosylated N-glycan (Figure 2). It was further 
verified that the structures of L1 and L3 were hybrid 
biantennary N-glycans of NA2 and NA2F, as they were 
shifted two residues forward after -galactosidase diges- 
tion (Figure 3). The levels of L1, L2 and L3 were not 
changed after treatment with N-acetylhexosaminidase, 
indicating they contain neither agalacto nor branched 
fucose structures. Taking together, L1 and L2 repre- 
sented NA2 and M8, respectively. As L3 was digested 
partially with α-1,2-mannosidase and α-1,6 fucosidase, it 
is clear that L3 represented a mixture of two structures: high 
mannose (Man9) and a-1,6 fucosylated N-glycan NA2F.  
 
 
Figure 3. Exoglycosidase sequencing of N-glycans from liver 
glycoproteins. The upper two panels show separations of de- 
sialylated serum N-glycans and digested with -galactosidase 
as reference. The lower two panels show separations of desia-
lylated liver N-glycans and digested with -galactosidase. Peak 
L1 and L3 shifted two residues forwards to NGA2 and NGA2F 
after removal of two galactoses. The arrows indicate the changes 
in the glycan peaks due to glycosidase digestion. The symbols 
used in the structural formulas are the following: “black square” 
stands for N-acetylglucosamine (GlcNAc); “open circle” stands 
for galactose; “grey triangle” stands for α-1,6-linked fucose; 
“grey circle” stands for mannose.  
3.2. Altered Glycosylation in the Liver of Patients 
We previously reported changes in serum N-linked gly-
cosylation in conjunction with the development of hepa-
tocellular carcinoma. To see whether N-glycans are al-
tered in liver tissue during HCC development, we deter-
mined the liver desialylated N-glycan profiles in HCC 
patients (n = 9), cirrhosis patients (n = 11) and healthy 
liver donors (n = 15). The N-glycan profile was altered in 
the livers of cirrhosis and HCC patients compared to the 
donors (Figure 4(a)). The level of L2, which is a high 
mannose N-glycan (M8), was significantly (p < 0.0001) 
decreased in the liver of cirrhosis and HCC patients com-
pared to the donors (Figure 4(b)). This result shows that 
glycosylation is altered in liver tissue during develop-
ment of HCC.  
 
 
Figure 4. Altered N-glycosylation in liver during pro- 
gress of cirrhosis and HCC. Desialylated N-glycan 
profiles in the liver revealed a decreased level of L2 in 
cirrhosis and HCC group (a). The value of log (L1/L2) 
showed significantly difference between control, cir- 
rhotic and HCC groups (b). The vertical axis repre- 
sents the glycan values of log (L1/P2). Error bars rep- 
resent 95% confidence intervals for means. Statistical 
significance of differences between groups is indicated 
by the p value. 
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3.3. Increased Fucosylation during Progression 
of HCC  
liver, indicating that fucosylation increases during pro- 
gression of HCC and cirrhosis (Figure 5(a)). To verify 
whether this was due to an increase in core α-1,6-fuco- 
sylation of N-glycans, we performed western blot with a 
probe of AOL (Aspergillus oryzae), which has strongest 
preference for the α-1,6-fucosylated glycans [15]. The 
result showed a higher level of total core fucose residues 
in livers with cirrhosis and HCC than in healthy control 
livers (Figure 5(b)). The total glycoproteins were de-
tected using Concanavalin A (ConA) lectin, which binds 
specifically to certain structures in glycoproteins, mainly 
internal and nonreducing terminal alpha-mannosyl groups. 
There was no significantly different total in glycan pro- 
teins among control, HCC and liver cirrhosis groups (Fi- 
gure 5(c)). 
Fucosylation is one of the most common modifications 
of oligosaccharides on glycoproteins and glycolipids. To 
determine the level of fucosylation in HCC liver, the 
probes of lectins, which are carbohydrate-binding or 
carbohydrate cross-linking proteins, was used for west-
ern blot analyses. A probe of AAL (Aleuria aurantia 
lectin) isolated from Aleuria aurantia mushrooms, which 
binds preferentially to fucose linked (α-1,6) to N-acetyl- 
glucosamine, or to fucose linked (α-1,3) to N-acetyllac- 
tosamine-related structures was used. The binding of 
AAL to liver glycoproteins was considerably increased 
in livers with HCC and cirrhosis compared to control  
 
 
Figure 5. SDS-PAGE of proteins from liver and western blots probed with lectin. The upper 
panel shows a western AAL and AOL blots of serum proteins (a) and (b). The lower panel 
shows a western blot of liver proteins probed with ConA (c) and a gel stained with Coomassie 
Blue (CBB) of the same proteins (d). The lanes are as follows: 1 - 3: controls; 4 - 6: cirrhosis; 7 
- 9: HCC. The data were reproducible in three independent experiments. The molecular weight 
of proteins were indicated. 
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3.4. Correlation of the Fucosylation Level with 
AFP  
The AST/ALT ratio is considered a sensitive marker of 
cirrhosis progression in viral hepatitis [16]. γ-glutamyl- 
transferase (GGT) has also been shown to have good 
sensitivity at the stage when viral hepatitis starts to cause 
structural damage [17]. However, we did not found sig- 
nificant differences between the HCC and cirrhosis 
groups in AFP, GGT or the AST/ALT ratio (Table 1). 
Pearson correlation showed that log (L1/L2) was not 
correlated with GGT and AST/ALT ratio, but positively 
correlated with AFP (r = 0.646; p < 0.0001).  
4. DISCUSSION 
Alteration of liver function during progression of HCC 
and cirrhosis affects the metabolism of glycoproteins and 
their concentration and secretion [18]. By analyzing the 
N-glycan profiles of liver tissue, we found that fucosyla- 
tion increased in the livers of HCC and cirrhosis patients.  
Glycoproteins are first formed in the ER from a vari- 
ety of oligomannose N-linked glycans (high-mannose) 
and then transported to the Golgi. Removal of some man- 
nose residues and further modification with a variety of 
different monosaccharides in the Golgi leads to form the 
three major classes of N-linked saccharides: high-man-
nose oligosaccharides, complex oligosaccharides and hy- 
brid oligosaccharides. Whether an N-glycan is high-man- 
nose or complex is thought to depend on its accessibility 
to the various saccharide-modifying proteins in the Golgi. 
This study detected a decrease in high-mannose N-glycans 
(M8 and M9) in the livers of HCC patients in compari-
son to healthy donors. This observation suggests that 
original high-mannose forms are more likely to be tri- 
mmed and then modified by the addition of other types 
of groups during progression of HCC. The altered modi- 
fication of glycoproteins during progression of HCC 
could affect the secretion of N-glycosylated proteins by 
liver cells. 
The appearance of core fucosylation on many glycol- 
proteins present in the circulation correlates with HCC 
[19]. It has been reported that core-1,6-fucosylation of 
haptoglobin [20], α-fetal protein (AFP) [21] and α1 anti-
trypsin [22] in serum is increased in liver diseases. Our 
previous study also showed alteration of the total serum 
N-glycome in HCC [7,23] and cirrhosis [11,24]. There-
fore, the detection of an increase in total core α-1,6- 
fucose in the liver of HCC and cirrhosis patients com-
pared to healthy volunteers, which indicates that the al-
teration in the total serum N-glycome in liver HCC and 
cirrhosis is, at least partly, due to modification of N- 
glycoproteins in the liver. The alteration of fucosylation 
could affect secretion of hepatic glycoproteins into the 
bile duct. Fucosyltransferase (Fut8) knockout mice have 
a lower level of α1-antitrypsin and α1 acid glycol- pro-
tein in bile than wild type mice, which suggests that core 
fucosylation could be a signal for secretion in the bile 
duct [25]. Increased fucosylation in HCC has been at-
tributed to an increase in both the α-1-6 fucosyltrans- 
ferase (Fut8) and its substrate, GDP-fucose [26]. How- 
ever, expression of Fut8 and GDP-fucose synthesis in 
liver were barely detectable by qPCR. Nevertheless, fuco- 
sylation is strongly associated with cancer, and more 
information about the mechanism involved and detection 
of other fucosylated glycoproteins would be highly de- 
sirable. 
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